Every Form 4 that TriSalus Life Sciences, Inc. (TLSI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TLSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSI filings page.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported a routine tax-related share withholding. The company withheld 14,650 shares of common stock at $4.46 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Patience directly holds 261,107 shares of TriSalus common stock.
TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.
TriSalus Life Sciences, Inc. Chief Medical Officer Richard Henry received new equity compensation in the form of restricted stock units and stock options. He was granted 60,000 shares of common stock as restricted stock units, which will vest in four equal annual installments starting on June 29, 2027, assuming continued service. He also received an employee stock option for 120,000 shares of common stock at an exercise price of $4.74 per share, vesting over four years with one-fourth vesting on June 29, 2027 and the remainder monthly thereafter. Following these grants, he directly holds 90,000 shares of common stock and 253,000 stock options.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.
TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.
Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.
TriSalus Life Sciences Chief Financial Officer Patience David bought 7,100 shares of the company’s Common Stock in an open-market transaction at $2.43 per share on May 15, 2026. Following this purchase, she directly owns 275,757 Common Stock shares.
TriSalus Life Sciences, Inc. director Gary B. Gordon reported an open-market purchase of company stock. On May 15, 2026, he bought 10,000 shares of Common Stock at $2.46 per share, increasing his direct ownership to 72,510 shares after the transaction.
TriSalus Life Sciences director Kerry R. Hicks reported new equity awards and updated holdings. Hicks received 28,201 restricted stock units payable in common stock, which fully vest on May 14, 2026, subject to continued service. He was also granted 56,403 director stock options with a $2.52 exercise price, expiring on May 13, 2036, that vest on the same date. Following these grants, Hicks directly holds 542,790 shares of common stock and 145,625 director stock options. Indirect holdings include 1,370,028 shares through HW Investment Partners, LLC, 322,737 shares via The Kerry Raymond Hicks Dynasty Trust, and 81,845 shares held by Millennium Trust Company, LLC, with beneficial ownership in certain entities disclaimed except for his pecuniary interest.
TriSalus Life Sciences director Mats Wahlstrom reported new equity compensation grants. He received 34,226 restricted stock units that vest fully on May 14, 2026, payable in common stock, subject to his continued board service.
He also received a Retainer RSU Award of 37,602 units, taken in lieu of 2026 cash board retainer fees. These RSUs vest in three equal quarterly installments through the remainder of 2026, conditioned on continued service. In addition, he was granted a director stock option for 75,204 shares of common stock at an exercise price of $2.5200 per share, vesting in full on May 14, 2026 and expiring on May 13, 2036.
The filing also shows substantial indirect common stock holdings through Leonard Capital LLC and HW Investment Partners, LLC, where Wahlstrom shares voting and investment discretion, and he disclaims beneficial ownership of HW Investment securities beyond his pecuniary interest.
TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.
One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.
TriSalus Life Sciences director David J. Matlin reported equity compensation grants. He received 23,065 restricted stock units that vest in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.
He also received 28,201 restricted stock units in lieu of 2026 board service retainer cash fees; these vest in three equal quarterly installments through the remainder of 2026, subject to continued service. In addition, he was granted options to purchase 56,403 shares of common stock at an exercise price of $2.52 per share, vesting in full on the one-year anniversary of the May 14, 2026 grant date. Following these awards, Matlin directly holds 1,323,210 shares of common stock and 121,403 stock options.
TriSalus Life Sciences director William Valle reported equity compensation grants. He received 24,553 restricted stock units and 28,201 additional restricted stock units, both payable in common stock. One award is in lieu of 2026 board retainer cash fees and vests in quarterly one-third installments through 2026.
Valle was also granted a director stock option for 56,403 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036. The RSU awards and option generally vest on the one-year anniversary of the May 14, 2026 grant date, subject to his continued service with the company.
TriSalus Life Sciences director Michael P. Stansky reported new equity awards and updated holdings. He received two grants of restricted stock units covering 20,089 and 23,501 shares of common stock, both payable solely in stock. One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date, while the retainer RSU award vests in three equal quarterly installments through the remainder of 2026, each subject to his continued board service.
He was also granted a director stock option for 47,003 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036, which will fully vest one year after the grant date if he continues serving. Following these grants, he holds 830,722 common shares directly and 199,698 shares indirectly through Skyview Investments LLC, where he serves as managing member with voting and dispositive power, along with 139,540 director stock options.
Frankenius Equity AB, a more than 10% holder of TriSalus Life Sciences, Inc., converted its entire Series A Convertible Preferred Stock into common shares. On July 31, 2025, it exchanged 230,000 preferred shares for 759,000 shares of common stock under a company exchange offer.
The offer calculates common shares using the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares, replacing its prior preferred position with ordinary equity.
TriSalus Life Sciences director David J. Matlin converted preferred stock into common shares under a company offer. On July 31, 2025, all 100,000 shares of Series A Preferred Stock held by Matlin were converted into 330,000 shares of common stock.
The conversion followed an exchange offer allowing all preferred holders to receive common shares equal to the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Matlin directly owned 1,271,944 common shares and no remaining preferred shares.
TriSalus Life Sciences, Inc. executive Jodi Devlin, Chief of Clinical Operations, reported three transactions in common stock. Across 3,207 shares, stock was sold at prices between $4.09 and $4.13 per share to satisfy tax withholding obligations tied to previously vested restricted stock units. A footnote explains these sales were made solely to cover taxes and were not discretionary. Following the most recent transaction, Devlin directly holds 97,364 shares of TriSalus common stock.
TriSalus Life Sciences Chief of Research Bryan F. Cox reported automatic sales of common stock to cover taxes on vested restricted stock units. Across three trades on March 11, 12 and 16, 2026, a total of 3,184 shares were sold around $4.09–$4.13 per share, leaving him with 163,415 directly held shares. A footnote explains these sales were solely to satisfy tax withholding obligations and were not discretionary.
TriSalus Life Sciences Chief Commercial Officer Richard Marshak reported routine share disposals tied to tax withholding, not discretionary selling. Over three days, he disposed of a total of 3,457 shares of common stock at prices between $4.09 and $4.13 per share. A footnote explains these shares were sold solely to satisfy tax obligations from vesting restricted stock units previously granted to him. After these transactions, Marshak continues to hold 110,397 shares of TriSalus common stock directly, indicating the disposals are small relative to his remaining stake.
TriSalus Life Sciences Chief Regulatory Officer Jennifer Stevens reported routine share sales tied to tax withholding. She sold a total of 3,530 shares of common stock in open-market transactions between March 11 and March 16 at prices around $4.09–$4.13 per share.
According to the disclosure, the shares were sold solely to satisfy tax obligations from vesting restricted stock units and do not represent discretionary sales. After these transactions, she continues to hold 124,110 TriSalus shares directly.
TriSalus Life Sciences CEO and President Mary T. Szela reported routine share dispositions tied to tax withholding, not discretionary selling. On March 17, she disposed of 15,944 shares of common stock at $3.85 per share. On March 11, she disposed of 4,358 shares at $4.13 per share. A footnote explains these shares were sold to satisfy tax obligations from vesting restricted stock units and that the activity does not represent a discretionary sale. After these transactions, she directly holds 752,987 common shares.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported an open-market purchase of 3,657 shares of common stock at $4.10 per share. Following this transaction, his directly owned stake increased to 268,657 shares, signaling additional personal capital committed to the company.
TriSalus Life Sciences director Gary B. Gordon purchased 9,756 shares of the company’s common stock in an open-market transaction at $4.10 per share on February 23, 2026. Following this purchase, he directly owns 9,756 common shares of TriSalus Life Sciences, Inc.
TriSalus Life Sciences director William Valle reported an open-market purchase of company stock. On this Form 4, he bought 30,487 shares of TriSalus Life Sciences, Inc. common stock at a price of $4.10 per share. Following this transaction, he directly owns 30,487 common shares.
TriSalus Life Sciences CEO Mary T. Szela reported an open-market purchase of 30,487 shares of common stock at $4.10 per share. After this buy, she directly owns 773,289 shares, increasing her personal stake in the company.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock. He bought 243,900 shares directly at $4.10 per share and 117,198 shares at $4.10 per share through Skyview Investments LLC.
After these transactions, his direct holdings total 787,132 common shares, and his indirect holdings through Skyview Investments LLC total 199,698 common shares, reflecting continued equity ownership aligned with the company’s shareholders.
TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief of Research. On November 24, 2025, the officer received 40,000 shares of common stock as a restricted stock unit award at a price of $0, increasing beneficial ownership to 166,599 common shares held directly. These RSUs vest in four equal annual installments starting November 24, 2025, conditioned on continued employment.
The officer was also granted an employee stock option to purchase 80,000 shares of common stock at an exercise price of $5.55 per share, expiring on November 23, 2035. One-fourth of the option vests on November 24, 2026, with the remaining portion vesting monthly thereafter, also subject to continued employment.
TriSalus Life Sciences, Inc. (TLSI) reported equity awards to its Chief of Clinical Operations on a Form 4. The officer received 50,000 shares of common stock as a restricted stock unit (RSU) award on November 24, 2025, which will vest in four equal annual installments starting on that date, conditioned on continued employment at each vesting date.
The officer was also granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $5.55 per share. One-fourth of the option shares vest on the one-year anniversary of the November 24, 2025 vesting commencement date, and the remaining shares vest monthly in equal installments over the following three years, also subject to continued employment. Following these grants, the reporting person beneficially owned 100,571 shares of common stock directly and 463,750 derivative securities in the form of options.
TriSalus Life Sciences (TLSI) reported new equity awards to its CEO and President, Mary Szela, in a Form 4 filing. She received 125,000 performance stock units (PSUs) on 02/13/2024 that vest upon achieving or exceeding $50 million of revenue over any 12‑month period ending on or before February 28, 2027. On 11/24/2025 she was granted 125,000 restricted stock units that vest in four equal annual installments starting November 24, 2025.
Also on 11/24/2025, she received 300,000 additional PSUs tied to achieving or exceeding $75 million of revenue over any 12‑month period ending on or before December 31, 2027, with 150,000 vesting upon achievement and 150,000 vesting one year later. She was further granted an option to buy 250,000 shares at $5.55 per share, expiring on 11/23/2035, vesting over four years. After these transactions, she beneficially owns 742,802 common shares and 1,578,182 derivative securities directly.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Regulatory Officer on a Form 4. On November 24, 2025, the officer received 50,000 restricted stock units payable in common stock at a price of $0, with the award vesting in four equal annual installments starting November 24, 2025, subject to continued employment. The filing also discloses an employee stock option to purchase 100,000 shares of common stock at an exercise price of $5.55 per share, with one-fourth vesting on the one-year anniversary of November 24, 2025 and the remainder vesting monthly over three years, also conditioned on continued employment.
After these transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, reflecting equity-based incentives tied to future service.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Commercial Officer on a Form 4. On November 24, 2025, the officer received 60,000 shares of common stock in the form of restricted stock units at a price of $0, bringing direct beneficial ownership of common stock to 113,854 shares after the transaction.
The same day, the officer was also granted an employee stock option to purchase 120,000 shares of common stock at an exercise price of $5.55 per share, with 408,937 derivative securities beneficially owned following the transaction. The RSUs vest in four equal annual installments starting on November 24, 2025, and the option vests over four years, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly through November 23, 2035, in each case subject to continued employment.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its chief financial officer in a Form 4 filing. On 11/24/2025, the officer received 65,000 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing beneficial ownership of common stock to 265,000 shares held directly.
The filing also reports an employee stock option grant to buy 130,000 shares of common stock at an exercise price of $5.55 per share, expiring on 11/23/2035. The RSU award vests in four equal annual installments starting 11/24/2025, while one-fourth of the option vests on the one-year anniversary of 11/24/2025 and the remaining shares vest monthly over the following three years, in each case subject to continued employment. Following this option grant, the officer beneficially owns 668,899 derivative securities directly.